Search
KAND567
go.drugbank.com/drugs/DB16511InvestigationalKAND567, a small molecule, blocks the fractaline (CX3CL1) receptor, which mediates the immune system response to inflammation[L32908]. … Because COVID-19 involves cytotoxic cells associated with this pathway, KAND567 is currently being tested as a treatment for those with the illness[L32908].
Zofin
go.drugbank.com/drugs/DB16519InvestigationalZofin, previously known as Organicell Flow, is a nanoparticle-based therapeutic derived from perinatal sources which is manufactured in a way that retains the naturally occurring microRNAs without the
Deoxyribonuclease I
go.drugbank.com/drugs/DB16523InvestigationalDeoxyribonuclease I (DNase I) is a human enzyme responsible for the digestion of extracellular DNA7[A227723]. It is normally found in saliva, urine, pancreatic secretions, and blood[A227723]. … Because of the hypothesis that increased concentrations of high-molecular-weight DNA is a factor for airway obstruction, abnormal viscoelastic properties of the sputum, and recurrent exacerbations of respiratory
KB109
go.drugbank.com/drugs/DB16531ExperimentalKB109 is a prebiotic to feed healthy bacteria for them to to outcompete multi-drug resistance organisms.
Zirconium dioxide
go.drugbank.com/drugs/DB16552InvestigationalCategories: Compounds used in a research, industrial, or household settingVitis vinifera seed
go.drugbank.com/drugs/DB16606InvestigationalCategories: Compounds used in a research, industrial, or household settingInfluenza A virus A/Vietnam/1194/2004 (H5N1) antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB16646ApprovedCategories: Inactivated Influenza A Virus VaccineSynonyms: Influenza A virus A/Vietnam/1194/2004 (H5N1) antigen (formaldehyde inactivated), Haemagglutinin-strain A (H5N1)Deucravacitinib
go.drugbank.com/drugs/DB16650ApprovedInvestigationalDeucravacitinib is a novel oral selective tyrosine kinase 2 (TYK2) inhibitor. … [A246938, A246943] This selectivity towards TYK2 may lead to an improved safety profile of deucravacitinib, as nonselective JAK inhibitors are associated with a range of adverse effects such as altered
Epcoritamab
go.drugbank.com/drugs/DB16672ApprovedInvestigational[L46516] It is administered subcutaneously and is currently being evaluated as a monotherapy and in combination for the treatment of a variety of hematologic malignancies. … Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
Mibavademab
go.drugbank.com/drugs/DB16673InvestigationalMibavademab is under investigation in clinical trial NCT04159415 (Study of REGN4461, a Leptin Receptor Agonist Antibody, in Patients With Generalized Lipodystrophy).